|
|
|
|
|
|
|
Thursday
|
|
15 October, 2026 |
|
|
|
|
|
|
|
|
|
|
With drugmakers still making billion-dollar US manufacturing pledges, we analyzed which states and companies are coming out on top — and Virginia and Eli Lilly are storming ahead. Read what we found below. |
|
|
|
Anna Brown |
Biopharma Breaking News Reporter, Endpoints News
|
|
|
|
|
|
|
by Anna Brown
|
The state of Virginia is emerging as an early winner as President Donald Trump prods drugmakers to increase their manufacturing investments in the US, securing... | |
|
|
|
|
|
|
by Anna Brown
|
GSK has budgeted more than $800 million to grow its Pennsylvania footprint, its second expansion in the state in two years. The company will... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
GSK will make up to 1,217 workers redundant from its sites in Belgium as part of the cost-cutting initiative CEO Luke Miels announced in July... | |
|
|
|
|
|
|
by Anna Brown
|
Plus more about Triastek, Scinai and HydRegen. NorthStar inks deal with Chinese CRO: Radioisotope maker NorthStar Medical Technologies has secureda partnership with Beijing-based contract... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
Curium has set the list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion — about a 5% discount to the cost... | |
|
|
|
|
|
|
|
Worldwide made. Thanks for reading.
|
|
|
|
|
|
|
|
